Takeda Pharmaceutical Company Limited and BioMarin Pharmaceutical Inc.: A Comprehensive Revenue Analysis

Takeda vs. BioMarin: A Decade of Revenue Growth

__timestampBioMarin Pharmaceutical Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20147510400001777824000000
Thursday, January 1, 20158898950001807378000000
Friday, January 1, 201611168540001732051000000
Sunday, January 1, 201713136460001770531000000
Monday, January 1, 201814912120002097224000000
Tuesday, January 1, 201917040480003291188000000
Wednesday, January 1, 202018604550003197812000000
Friday, January 1, 202118462750003569006000000
Saturday, January 1, 202220960390004027478000000
Sunday, January 1, 202324192260004263762000000
Monday, January 1, 202428539150004263762000000
Loading chart...

Cracking the code

A Decade of Revenue Growth: Takeda vs. BioMarin

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and BioMarin Pharmaceutical Inc. have showcased remarkable revenue trajectories over the past decade. From 2014 to 2023, Takeda's revenue surged by approximately 140%, reflecting its strategic acquisitions and robust product pipeline. In contrast, BioMarin, a leader in rare disease therapies, experienced a commendable 220% increase in revenue, underscoring its innovative approach and niche market focus.

Key Insights

  • Takeda's Dominance: By 2023, Takeda's revenue reached over 4.26 trillion, a testament to its expansive global footprint and diversified portfolio.
  • BioMarin's Niche Success: Despite its smaller scale, BioMarin's revenue growth highlights its success in the rare disease sector, with revenues peaking at 2.42 billion in 2023.

While Takeda's revenue data for 2024 remains consistent with 2023, BioMarin's data is yet to be revealed, leaving room for anticipation in the coming year.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025